ASCLEPIX THERAPEUTICS

asclepix-therapeutics-logo

AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to design long-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body. AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases.

#SimilarOrganizations #People #Financial #Website #More

ASCLEPIX THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Health Diagnostics Therapeutics

Founded:
2011-01-01

Address:
Baltimore, Maryland, United States

Country:
United States

Website Url:
http://www.asclepix.com

Total Employee:
11+

Status:
Active

Contact:
410-657-2627

Email Addresses:
[email protected]

Total Funding:
50 M USD

Technology used in webpage:
Domain Not Resolving Euro CrUX Top 50m CrUX Dataset


Similar Organizations

alaya-bioscience-logo

Alaya Bioscience

Alaya Bioscience is a biotech company that develops novel nanotherapeutics for the treatment of human diseases.

cedilla-therapeutics-logo

Cedilla Therapeutics

Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.

disarm-therapeutics-logo

Disarm Therapeutics

Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.

pliant-therapeutics-logo

Pliant Therapeutics

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.


Current Advisors List

joshua-barer_image

Joshua Barer Board Member @ AsclepiX Therapeutics
Board_member

kevin-slawin_image

Kevin Slawin Board Member @ AsclepiX Therapeutics
Board_member

not_available_image

Sapna srivastava Board Member @ AsclepiX Therapeutics
Board_member

chris-garabedian_image

Chris Garabedian Board Member @ AsclepiX Therapeutics
Board_member
2020-06-01

ben-askew_image

Ben Askew Board Member @ AsclepiX Therapeutics
Board_member
2020-06-01

Current Employees Featured

jordan-j-green_image

Jordan J. Green
Jordan J. Green CTO & Co-Founder @ AsclepiX Therapeutics
CTO & Co-Founder
2011-01-01

aleksander-popel_image

Aleksander Popel
Aleksander Popel Co-Founder & CSO @ AsclepiX Therapeutics
Co-Founder & CSO
2011-05-01

not_available_image

Amir Shojaei
Amir Shojaei Chief Scientific Officer, EVP-Clinical Development @ AsclepiX Therapeutics
Chief Scientific Officer, EVP-Clinical Development
2021-07-01

Founder


aleksander-popel_image

Aleksander Popel

jordan-j-green_image

Jordan J. Green

Investors List

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Series A - AsclepiX Therapeutics

hibiscus-capital-management_image

Hibiscus Capital Management

Hibiscus Capital Management investment in Series A - AsclepiX Therapeutics

rapha-capital-management_image

Rapha Capital Management

Rapha Capital Management investment in Series A - AsclepiX Therapeutics

barer-son-capital_image

Barer & Son Capital

Barer & Son Capital investment in Series A - AsclepiX Therapeutics

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Series A - AsclepiX Therapeutics

rapha-capital-management_image

Rapha Capital Management

Rapha Capital Management investment in Series A - AsclepiX Therapeutics

salem-partners_image

Salem Partners

Salem Partners investment in Convertible Note - AsclepiX Therapeutics

rapha-capital-management_image

Rapha Capital Management

Rapha Capital Management investment in Convertible Note - AsclepiX Therapeutics

piedmont-capital-partners_image

Piedmont Capital Partners

Piedmont Capital Partners investment in Convertible Note - AsclepiX Therapeutics

barer-son-capital_image

Barer & Son Capital

Barer & Son Capital investment in Convertible Note - AsclepiX Therapeutics

Official Site Inspections

http://www.asclepix.com Semrush global rank: 10.25 M Semrush visits lastest month: 240

  • Host name: 228.217.209.35.bc.googleusercontent.com
  • IP address: 35.209.217.228
  • Location: Mountain View United States
  • Latitude: 37.4043
  • Longitude: -122.0748
  • Metro Code: 807
  • Timezone: America/Los_Angeles
  • Postal: 94043

Loading ...

More informations about "AsclepiX Therapeutics"

AsclepiX Therapeutics - Crunchbase Company Profile …

Organization. AsclepiX Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. …See details»

About - AsclepiX Therapeutics

Co-founded by Aleksander S. Popel, PhD and Jordan J. Green, PhD at Johns Hopkins University, AsclepiX is building a …See details»

Contact - AsclepiX Therapeutics

Contact Us Your Name (required) Organization(required) Email Address (required) Telephone (required) Subject Your Message Contact Information Corporate Headquarters 5237 River …See details»

AsclepiX Therapeutics - LinkedIn

AsclepiX Therapeutics is a clinical-stage biopharmaceutical company leveraging computational biology from Johns Hopkins to identify and develop peptides for improved treatments of retinal …See details»

Asclepix Therapeutics, Inc. Company Profile | Baltimore, MD ...

Find company research, competitor information, contact details & financial data for Asclepix Therapeutics, Inc. of Baltimore, MD. Get the latest business insights from Dun & Bradstreet.See details»

About - AsclepiX Therapeutics

Co-founded by Aleksander S. Popel, PhD and Jordan J. Green, PhD at Johns Hopkins University, AsclepiX is building a company and culture focused on transforming the treatment of disease …See details»

AsclepiX Therapeutics Company Overview, Contact Details

Jul 26, 2023 AsclepiX Therapeutics is a clinical-stage biopharmaceutical company leveraging computational biology from Johns Hopkins to identify and develop peptides for improved …See details»

AsclepiX Therapeutics - Funding, Financials, Valuation & Investors

AsclepiX Therapeutics is a biotech company that develops novel therapeutics to revolutionize the treatment of retinal diseases and cancer. Search Crunchbase. ... How much funding has this …See details»

AsclepiX Therapeutics - VentureRadar

AsclepiX Therapeutics is a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular homeostasis that is disrupted in retinal and oncologic …See details»

AsclepiX Therapeutics - Org Chart, Teams, Culture & Jobs - The Org

AsclepiX Therapeutics. Join to edit. Join to edit. AsclepiX Therapeutics is revolutionizing the treatment of retinal diseases and cancer with a singular focus on the design, development, …See details»

AsclepiX Therapeutics - Contacts, Employees, Board Members

Organization. AsclepiX Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Contacts 6. About. AsclepiX Therapeutics …See details»

Careers - AsclepiX Therapeutics

At AsclepiX, the work is meaningful, the culture is inclusive, the company growth is rapid, and the rewards are plentiful. ... We have a competitive advantage that is enjoyed by no other …See details»

AsclepiX Therapeutics, Inc. Strengthens Board of Directors, …

Mar 25, 2019 As a Board Member, Dr. Altschuler will help AsclepiX succeed and scale as it commercializes its flagship product, AXT107, and their products for cancer. ... value-based …See details»

AsclepiX Therapeutics Raises $10M in Series A-3 Funding

Jul 26, 2023 AsclepiX Therapeutics, a Baltimore, MD-based clinical-stage biotech company leveraging computational biology to develop peptides for improved treatments of retinal …See details»

Series A - AsclepiX Therapeutics - 2023-07-26 - Crunchbase

Organization Name . AsclepiX Therapeutics . Announced Date Jul 26, 2023; Funding Type Series A; Funding Stage Early Stage Venture; Money Raised . $10M. Lead Investors. ... AsclepiX …See details»

AsclepiX secures $10 million in Series A-3 financing round - Healio

Jul 26, 2023 AsclepiX Therapeutics has secured $10 million in Series A-3 financing to advance the development of its lead clinical candidate, AXT107, for the treatment of neovascular retinal …See details»

Pipeline - AsclepiX Therapeutics

AsclepiX Therapeutics. Our Pipeline. Our lead product is AXT107, with additional follow on product candidates AXT201, AXT301 and AXT501. Our initial therapeutic focus for AXT107 is …See details»

Careers - AsclepiX Therapeutics

Ensure that RA/QA organization complies with all policies and standards. Ensure that all Corporate HR Policies and Programs are effectively implemented and respected by all …See details»

Jill Vazzano Tierney - Vice President Finance - AsclepiX ... - LinkedIn

A global, privately-held holding company with revenues of $1.6 billion that primarily engages in business process outsourcing, including, accounts receivable management, back office …See details»

linkstock.net © 2022. All rights reserved